Retatrutid research shows potential for obesity treatment

Research into Retatrutid, often discussed in the context of GLP-3, is exploring new perspectives on treating obesity and metabolic diseases. Retatrutid acts as a triple agonist, meaning it activates three different hormone receptors: GLP-1, GIP, and glucagon.

Lilly reported positive results from Phase 3 clinical trials, specifically the TRIUMPH-2 and TRIUMPH-3 studies, in July 2026. This approach aims to address various biological processes simultaneously by targeting multiple signaling pathways within the body.